Depression and anxiety measures by ISCED-97 educational level in all persons with iRMD and information on education (n=2883)
| n | n missing | Education level | |||
| Lower | Intermediate | Higher | |||
| Number of participants with an inflammatory rheumatic disease* | 2883 | 0 | 115 | 1313 | 1438 |
| Physician’s lifetime diagnosis of depression, % | 2866 | 17 | 39 | 27 | 23 |
| Depression treatment last 12 months, % of those with physician’s diagnosis of depression | 738 | 0 | 56 | 53 | 53 |
| MINI screen positive, % | 2841 | 24 | 44 | 39 | 38 |
| MINI classification positive, % of positive screened and with Level 2 | 291 | 2586 | 92 | 85 | 89 |
| PHQ-9 ≥10, % | 2535 | 348 | 27 | 16 | 12 |
| PHQ-9 sum score, mean±SD | 2535 | 348 | 7.2±5.4 | 5.4±4.6 | 4.9±4.4 |
| Physician’s lifetime diagnosis of anxiety, % | 2873 | 10 | 31 | 16 | 13 |
| GAD-7 sum score, mean±SD | 2525 | 358 | 5.6±4.5 | 4.2±4.1 | 3.9±3.8 |
| GAD-7 ≥10, % | 2525 | 358 | 21 | 11 | 8.2 |
| Stroop effect, mean±SD | 2671 | 212 | 27±15 | 24±13 | 21±10 |
| Semantic fluency (animal names), mean±SD | 2733 | 150 | 21±5.8 | 24±6.7 | 26±6.8 |
| Digit span backwards, mean±SD, range 2–9 | 2712 | 171 | 4.2±1.0 | 4.5±1.2 | 4.8±1.3 |
Based on NAKO data freeze 100 000.
*Includes self-reported physician diagnosis of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus or Sjögren disease.
GAD-7, General Anxiety Disorder-7 Scale; iRMD, inflammatory rheumatic disease; ISCED-9, International Standard Classification of Education 97; MINI, Mini International Neurospsychiatric Interview; PHQ-9, Depression Scale of the Patient Health Questionnaire.